Oncology research and treatment · 2025
Molecular Tissue Profiling in a Clinically Selected Pancreatic Cancer Cohort.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Hegenberg Stefanie, Germing Tobias, Schlageter Elena, Ekmekciu Ira, Christmann Jens, Tannapfel Andrea, Reinacher-Schick Anke
Аннотация
INTRODUCTION: Pancreatic ductal adenocarcinoma (PDAC) is a challenging malignancy and precision oncology treatment options may improve patient outcomes. Next-generation sequencing (NGS) is an established tool that enables multigene panel analysis.
METHODS: This NGS tissue-based analysis, conducted at a German pancreatic cancer center, included 128 patients between January 2016 and January 2021.
RESULTS: A targetable lesion was detected in 15.6% of patients. BRCA1/2 mutations were identified in 16 patients, of whom 13 had germline mutations; 8 of these patients received olaparib. In 41.4% of patients, homologous recombination repair genes were affected. Two cases of ATP1B1-NRG1 fusions and seven cases of dMMR tumors were found, leading to individualized treatment. KRAS mutations were present in 70.3%, and TP53 mutations were present in 63.3%. A total of 80.5% of patients received platinum-based chemotherapy, predominantly FOLFIRINOX.
CONCLUSION: The high frequency of targetable alterations in our cohort underscores upfront NGS testing in PDAC. Younger patients, those with a positive family history, and KRAS WT patients should be of particular interest.
METHODS: This NGS tissue-based analysis, conducted at a German pancreatic cancer center, included 128 patients between January 2016 and January 2021.
RESULTS: A targetable lesion was detected in 15.6% of patients. BRCA1/2 mutations were identified in 16 patients, of whom 13 had germline mutations; 8 of these patients received olaparib. In 41.4% of patients, homologous recombination repair genes were affected. Two cases of ATP1B1-NRG1 fusions and seven cases of dMMR tumors were found, leading to individualized treatment. KRAS mutations were present in 70.3%, and TP53 mutations were present in 63.3%. A total of 80.5% of patients received platinum-based chemotherapy, predominantly FOLFIRINOX.
CONCLUSION: The high frequency of targetable alterations in our cohort underscores upfront NGS testing in PDAC. Younger patients, those with a positive family history, and KRAS WT patients should be of particular interest.
Предметные рубрики MeSH
HumansPancreatic NeoplasmsFemaleMiddle AgedMaleAgedCarcinoma, Pancreatic DuctalHigh-Throughput Nucleotide SequencingAntineoplastic Combined Chemotherapy ProtocolsAdultProto-Oncogene Proteins p21(ras)Aged, 80 and overPrecision MedicineBiomarkers, TumorLeucovorinMutationCohort StudiesIrinotecanGerm-Line MutationOxaliplatinBRCA2 ProteinBRCA1 ProteinFluorouracilPhthalazinesPiperazines